Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)

BACKGROUND: On the basis of the results of two pivotal phase III clinical trials, eribulin mesylate is currently approved in EU for the treatment of advanced breast cancer (aBC) in patients who have previously received an anthracycline and a taxane in either the adjuvant or the metastatic setting, a...

Full description

Saved in:
Bibliographic Details
Published in:ESMO Open
Main Authors: Orditura, Michele, Gravina, Adriano, Riccardi, Ferdinando, Diana, Anna, Mocerino, Carmela, Leopaldi, Luigi, Fabozzi, Alessio, Giordano, Guido, Nettuno, Raffaele, Incoronato, Pasquale, Barzelloni, Maria Luisa, Caputo, Roberta, Pisano, Agata, Grimaldi, Giuseppe, Genua, Geppino, Montesarchio, Vincenzo, Barbato, Enrico, Iodice, Giovanni, Lieto, Eva, Procaccini, Eugenio, Mabilia, Roberto, Febbraro, Antonio, Laurentiis, Michelino De, Ciardiello, Fortunato
Format: Artigo
Language:Inglês
Published: BMJ Publishing Group 2017
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5519815/
https://ncbi.nlm.nih.gov/pubmed/28761747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2017-000176
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items